Loading company…
Primaa develops Cleo, an AI-powered software tool that helps pathologists diagnose breast and skin cancer.
Founded in 2018 in Paris, France, Primaa SAS develops AI-powered software for cancer diagnosis. Its Cleo platform helps pathologists diagnose breast and skin cancer through image analysis and deep learning, and it has received CE marking. The company serves hospitals, diagnostic laboratories and healthcare institutions, mainly in France, Germany and other European countries, and is led by CEO Fanny Massart. It raised EUR 2.15 mn in a Series B round in July 2022 and EUR 7 million from new investors MH Innov, Elaia Partners, SWEN Capital Partners and Super Capital VC in October 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in